Efficacy of Fluoxetine - a Trial in Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1500 participants.
Also called NCT02683213
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,500 participants
- Registry
-
NCT02683213 -
2011-006130-16
-
- Other papers using this trial's data
- Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial
- Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02683213. Randomized; quadruple masking; primary purpose treatment. Start 2014-10-20 (actual); primary completion 2020-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Fluoxetine - a Trial in Stroke
- Acronym
- EFFECTS
- Condition
- Stroke
- Intervention (Drug)
- Fluoxetine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Karolinska Institutet
- Collaborator
- The Swedish Research Council
- Collaborator
- Swedish Heart Lung Foundation
- Collaborator
- Stroke-Riksförbundet
- Collaborator
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Collaborator
- Hjärnfonden (The Swedish Brain foundation)
- Collaborator
- The Swedish Medical Association
Record details
- Record id
cardio:ct-nct02683213- Content hash
2c6a89fe1984ffd0b4d178cb9a09eb1fbc504ba7aa4e9fd62f88d678dd52fac2